The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

Amsterdam-based UniQure developed AMT-130 to slow progression of Huntington's disease, a fatal, progressive neurodegenerative disease caused by mutations in the huntingtin gene. The gene therapy is ...

Three patients reportedly died after side effects from Novartis' rap-cel, and BMS has observed some inflammatory events in patients after zola-cel.

After discussions with the FDA, the firm believes it has a regulatory path to bringing Illuccix and Gozellix into the pre-biopsy setting.

Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment ...

AstraZeneca will also share data with regulators from a Phase III study of Tagrisso and Orapthys in lung cancer.

The firm is seeking to expand the indication for its siRNA drug, which is already approved for familial chylomicronemia syndrome.

NEW YORK – Abbisko Therapeutics has begun treating cancer patients harboring KRAS alterations with the pan-KRAS Inhibitor ABSK211 in a Phase I trial.

In search of a molecular diagnosis for a child with bilateral vestibular schwannomas, a family undergoes a diagnostic odyssey ...

Sangrail Biologics is already discussing with the FDA a regulatory path for the gene therapy that Abeona Therapeutics dropped ...